Punjabi Waffen
RESEARCH or ROT
- Joined
- Feb 23, 2025
- Posts
- 8,699
- Reputation
- 12,074
FGFR3 INHIBITORS FOR GROWTH AND KEEPING GROWTH PLATES OPEN
Vosoritide, Infigratinib, and TYRA300
॰═════════════════॰
HOW BONES GROW AND WHY GROWTH PLATES CLOSE
॰═════════════════॰
The Growth Plate
Long bones grow from the ends at a structure called the growth plate or epiphyseal plate. This is a layer of cartilage between the end of the bone (the epiphysis) and the shaft (the diaphysis). The growth plate is where new bone is made, and it stays open during childhood and adolescence. Once it closes, usually in the late teens, height increase stops permanently.
The growth plate has several zones:
Resting zone
stem like cells that can become new cartilage cells
Proliferative zone
cells divide rapidly, stacking into columns like coins
Hypertrophic zone
cells swell up and prepare to turn into bone
Calcification zone
cartilage turns into hard bone
For height to increase, the proliferative and hypertrophic zones need to stay active. Anything that slows these zones down reduces growth velocity.
Endochondral Ossification
Endochondral ossification is the process where cartilage is replaced by bone. This is how all long bones grow in length. It requires a balance between cartilage cell production, swelling, and replacement by bone. If this balance is disrupted, bones grow shorter or stop growing early.
What Closes Growth Plates
Growth plates close when estrogen levels rise during puberty. Estrogen speeds up the rate at which cartilage cells in the growth plate turn into bone, eventually using up all the cartilage and fusing the epiphysis to the diaphysis. Once fused, the plate is closed and no more length can be added.
Some factors that keep growth plates open longer:
Lower estrogen levels delayed puberty or aromatase inhibitors
Growth hormone stimulates IGF1 which supports growth plate activity
Thyroid hormone necessary for normal growth plate function
Proper nutrition calories, protein, carbs, fats, vitamins, and minerals
Factors that close them early:
High estrogen
puberty, exogenous estrogen exposure
FGFR3 overactivity the focus of this thread
Chronic illness
malnutrition, inflammation, corticosteroid use
Trauma or infection
direct damage to the growth plate
॰═════════════════॰
FGFR3 AND DWARFISM
॰═════════════════॰
What FGFR3 Does Normally
FGFR3 is a receptor on cartilage cells in the growth plate. Its job is to act as a brake on bone growth. When FGFR3 gets a signal, it slows down cartilage cell division and speeds up their maturation into bone. This is a normal safety mechanism to prevent bones from growing too long.
Under normal conditions, FGFR3 signaling is balanced. It keeps growth in check but does not stop it completely.
When FGFR3 Is Broken
In achondroplasia, the most common form of dwarfism, a mutation in the FGFR3 gene makes the receptor stuck in the "on" position. Over 99% of achondroplasia cases are caused by the G380R mutation. This means the brake is slammed on all the time.
The result:
Proliferative zone shrinks
fewer cells dividing
Hypertrophic zone shrinks
less swelling and preparation for bone
Resting zone expands abnormally
stem cells get stuck and do not differentiate
Bones grow much slower
especially the long bones of the arms and legs
Disproportionate short stature
limbs are short relative to trunk
Other FGFR3related conditions:
Hypochondroplasia milder form, caused by N540K or other mutations
Severe achondroplasia with developmental delay and acanthosis
nigricans (SADDAN)
severe form
Thanatophoric dysplasia
lethal form, incompatible with life
Why Inhibiting FGFR3 Helps
If the problem is FGFR3 being stuck on, the solution is to turn it down. By blocking or inhibiting FGFR3 signaling, the brake is released. Cartilage cells can divide more, swell more, and the growth plate stays active longer. This leads to:
Increased growth velocity
faster height gain
Longer bones
especially femur and tibia
Better body proportions
reduced difference between upper and lower body segments
Larger foramen magnum
the opening at the base of the skull, reducing risk of life-threatening compression
Improved spinal shape
longer vertebrae and better disc shape, reducing spinal stenosis risk
This is the rationale behind all FGFR3 targeted therapies for growth.
Can This Work in Normal People
This is the big question. FGFR3 is not just broken in dwarfism it is active in everyone. Even in people with normal height, FGFR3 puts a brake on growth. If you inhibit FGFR3 in someone with normal FGFR3, you might:
Increase growth velocity
shown in wild-type mice treated with TYRA-300
Keep growth plates open longer
potentially delaying closure
Add extra height
if used before plates close
However, this is untested in humans without FGFR3 mutations. The data come from mouse studies and anecdotal reports from pediatric cancer patients receiving pan FGFR inhibitors who experienced accelerated growth. There are also risks:
Slipped capital femoral epiphysis
the growth plate can slip under too much growth pressure, requiring surgery
Unknown long-term bone quality
faster growth might mean weaker bones
Other FGFR3 functions
FGFR3 also plays roles in hearing, skin, and wound healing
The pediatric oncology cases are informative. Several children without short stature conditions received pan FGFR inhibitors for cancer and experienced annualized growth velocities above the normal range. Some developed slipped capital femoral epiphysis, a serious hip condition, attributed to the accelerated growth. This suggests FGFR inhibition can promote growth even without a genetic FGFR3 problem, but the risk benefit ratio needs careful evaluation.
॰═════════════════॰
VOSORITIDE VOXZOGO
BioMarin
॰═════════════════॰
Overview
Vosoritide is a recombinant Ctype natriuretic peptide (CNP) analog. CNP is a natural hormone in the body that counteracts FGFR3 signaling. Vosoritide is basically a lab made version of CNP that lasts longer in the body. It was approved by the FDA in November 2021 for children 5 years and older with achondroplasia who have open growth plates. In October 2023, approval was expanded to children under 5.
It is given as a daily subcutaneous injection (shot under the skin), which is a significant burden for families.
How It Works
Vosoritide binds to natriuretic peptide receptor B (NPR-B) on cartilage cells. This triggers production of cyclic guanosine monophosphate (cGMP), a signaling molecule inside the cell. cGMP then blocks the MAPK/ERK pathway, which is the main growth suppressing signal coming from FGFR3.
basically FGFR3 is the brake pedal. CNP/vosoritide is the hand that pulls the brake pedal back up, releasing it. The brake is still there, but it is not being pressed as hard.
Importantly, vosoritide does not directly block FGFR3. It works downstream, counteracting the signal. This means it is less potent than direct FGFR3 inhibitors but also has a different safety profile.
Clinical Results Phase 3
The pivotal trial enrolled 121 children with achondroplasia.
Annualized growth velocity increased by 1.57 cm/year compared to placebo (95% CI 1.22-1.93, p<0.0001)
AGV rose from 4.26 cm/year to 5.57 cm/year on treatment
Sustained efficacy over 156 weeks (3 years)
At 182 weeks, AGV remained stable at 5.45 cm/year
Improved body proportions
upper to lower body segment ratio improved by -0.05
85% of experts predicted meaningful proportionality gains for children starting between age 2 and puberty
Dosing
15 mcg/kg once daily by subcutaneous injection
Given at approximately the same time each day
Injected into fatty tissue under the skin (abdomen, thigh, or back of arm)
Side Effects and Management
Injection site reactions
redness, swelling, pain at injection site
Management: rotate injection sites, apply ice, use topical anesthetic cream before injection
Vomiting (20%)
take with food, antinausea medication if needed
Blood pressure drop
transient hypotension after injection
inject at bedtime to sleep through the effect, ensure adequate hydration
Hyperhidrosis (excessive sweating)
usually mild and self limiting
Limb pain
OTC pain relievers, rest
No hyperphosphatemia
because vosoritide does not block FGFR1 in the kidneys
No eye toxicity because it does not block FGFR2
No skin toxicity
because it does not block FGFR4
The main downside is the daily injection burden and the need for refrigeration. Compliance can be challenging for families.
making it a mogger compouns.
Limitations
Only works while growth plates are open
Requires daily injections
Moderate effect size (1.57 cm/year extra growth)
Does not address the root cause (FGFR3 is still overactive)
Very expensive
॰═════════════════॰
Links
FDA Voxzogo Vosoritide Label
PMC12352272 - Vosoritide Review Clinical and Real-World Evidence
Rare Disease Advisor - Achondroplasia Management Vosoritide
॰═════════════════॰
INFIGRATINIB PROPEL 3
BridgeBio
/
QED Therapeutics
॰═════════════════॰
Overview
Infigratinib is an oral FGFR13 inhibitor that was originally developed for cancer but is now being repositioned for achondroplasia at much lower doses. The PROPEL 3 Phase 3 trial was completed in early 2026 with positive results. This is the first oral drug to show statistically significant improvements in both growth velocity and body proportionality in achondroplasia.
BridgeBio plans to submit for FDA approval in the second half of 2026. It has already received Breakthrough Therapy and Orphan Drug designation from the FDA.
How It Works
Unlike vosoritide, which works downstream of FGFR3, infigratinib directly blocks FGFR3 at the source. It is an oral pill that inhibits the FGFR3 enzyme, preventing it from sending growth suppressing signals. At the low doses used for achondroplasia, it is selective enough to hit FGFR3 without causing the severe side effects seen at cancer doses.
Preclinical Data
In mouse models of achondroplasia:
Daily treatment at 2 mg/kg significantly increased bone growth
Low doses of 0.2 and 0.5 mg/kg also worked
Intermittent dosing (1 mg/kg every 3 days) was effective
Improved skull shape and enlarged foramen magnum
No changes in FGF23 or phosphorus levels at low doses
Positive impact on cartilage cell differentiation in the growth plate
PROPEL 3 Phase 3 Results
A global one year randomized double blind placebo controlled trial in children aged 3 to under 18 with achondroplasia and open growth plates.
Primary endpoint met
Change in annualized height velocity superior to placebo
Mean treatment difference +2.10 cm/year
LS mean treatment difference +1.74 cm/year (p<0.0001)
Secondary endpoints
Absolute AHV at Week 52: 5.96 cm/year vs 4.22 cm/year on placebo
Height Z-score improvement: +0.32 SD vs placebo (p<0.0001)
Largest improvement on treatment arm: +0.41 SD
Body proportionality
first drug to show statistically significant improvement
In children under 8 (over 50% of participants)
LS mean decrease in upper-to-lower ratio -0.05 vs placebo (p<0.05)
Overall population: LS mean decrease -0.05, treatment difference -0.02 vs placebo
Safety in PROPEL 3
No discontinuations due to side effects
No serious side effects related to the drug
Only 3 cases (4%) of hyperphosphatemia, all mild, temporary, without symptoms, and not requiring dose changes or stopping
No eye problems associated with FGFR1 or FGFR2 inhibition
No side effects seen with CNP analogs like blood pressure drops, injection site reactions, or excessive hair growth
This safety profile is dramatically better than the cancer dose because the achondroplasia dose is much lower.
Dosing for Growth
0.25 mg/kg/day oral once daily
This is roughly 1/500th of the cancer dose (125 mg/day), yet some people fearmonger and take 1mg
Much lower exposure means much less toxicity
Advantages Over Vosoritide
Oral pill
no injections
Once daily
easier than daily shots
Direct mechanism
blocks FGFR3 at the source rather than counteracting it downstream
Better body proportionality
first drug to show significant improvement
Potentially stronger effect
5.96 cm/year absolute AHV is among the highest reported
Ongoing Trials
PROPEL Infant and Toddler
study in children from birth to under 3 years
॰═════════════════॰
Links
BridgeBio PROPEL 3 Results
PubMed 38590263 - Low-Dose Infigratinib in Achondroplasia Mouse Model
EMPR - Infigratinib Improves Growth in Children
Rare Disease Advisor - PROPEL 3 Results
॰═════════════════॰
TYRA-300
Tyra Biosciences
॰═════════════════॰
Overview
TYRA300 is an also oral selective FGFR3 inhibitor being developed for both cancer and achondroplasia. It is the first drug designed to hit only FGFR3 while sparing FGFR1, FGFR2, and FGFR4. This selectivity is expected to eliminate the side effects that come from blocking the other FGFRs.
How It Works
TYRA 300 was designed using computer modeling to fit the exact shape of the FGFR3 enzyme. It binds to FGFR3 with over 100x selectivity compared to the other FGFRs. This means:
No FGFR1 blockade
no hyperphosphatemia
No FGFR2 blockade
no eye problems
No FGFR4 blockade
no liver or skin issues
Direct FGFR3 inhibition
stronger effect on the root cause
Preclinical Results in Mice
TYRA300 was tested in three types of mice:
Normal wild-type mice:
14 mg/kg increased nose-to-tail length by 7.3%
Tibia length increased 6.4%
Femur length increased 8.2%
Dose-dependent growth
more drug meant more growth
This proves FGFR3 inhibition can increase growth even in normal animals
Achondroplasia model mice (Fgfr3 Y367C/+)
Increased nose to tail, tail, tibia, and femur length
Partially restored normal body proportions
Growth plate zones expanded
more proliferative and hypertrophic activity
Improved skull shape and enlarged foramen magnum
Better bone mineral density and bone volume
Hypochondroplasia model mice (Fgfr3 N534K/+)
Femur increased 3.70%
Tibia increased 3.75%
Ulna increased 5.03%
Humerus increased 3.22%
Mechanism in Growth Plate
TYRA300 increased both proliferation (cell division) and differentiation (maturation) of cartilage cells in the growth plate. It restored type X collagen staining, which is a marker of healthy hypertrophic zone function. It also improved spinal shape longer lumbar vertebrae and better disc shape.
The foramen magnum (the hole at the base of the skull where the spinal cord passes through) was significantly enlarged. This is critical because foramen magnum stenosis is a life threatening complication in babies with achondroplasia.
Clinical Trials for Growth
BEACH301 Phase 2 NCT06995677
Status: Actively recruiting (sumbit your sons, if you have a kid)
Population: Children 3 to 10 years with achondroplasia and open growth plates
Design: Open label, multicenter
Goal: Evaluate safety and growth effects
Advantages
Oral pill
no injections
Selective for FGFR3 only
expected to have the cleanest safety profile
Works in both achondroplasia and hypochondroplasia
May work in other short stature conditions
preclinical data in normal mice suggest broader applicability
Improves both growth and bone quality
Safety Profile
Based on preclinical selectivity
No hyperphosphatemia
FGFR1 spared
No eye toxicity
FGFR2 spared
No liver or skin issues
FGFR4 spared
Unknown long-term effects
clinical data pending
Potential bone concerns
FGFR3 also plays roles in hearing, skin, and wound healing
॰═════════════════॰
Links
PMC12128972 - TYRA-300 Preclinical Bone Growth Data
JCI Insight - TYRA-300 Bone Growth Study
Rare Disease Advisor - TYRA-300 Preclinical Results
NCT06995677 - BEACH301 Phase 2
॰═════════════════॰
COMPARATIVE OVERVIEW
॰═════════════════॰
Mechanism Comparison
Vosoritide
Indirect. Mimics CNP, works downstream of FGFR3 by boosting cGMP and blocking MAPK/ERK. Does not touch FGFR3 directly.
Infigratinib
Direct. Blocks FGFR1-3 enzymes. At low doses, mainly hits FGFR3.
TYRA-300
Direct and selective. Blocks only FGFR3, spares FGFR1/2/4.
Route of Administration
Vosoritide Daily subcutaneous injection
Infigratinib Oral once daily
TYRA-300 Oral once daily
Efficacy Comparison
Vosoritide +1.57 cm/year extra growth, AGV 5.57 cm/year
Infigratinib +1.74 to +2.10 cm/year extra growth, AGV 5.96 cm/year, first to improve body proportionality significantly
TYRA-300 Preclinical only, but showed dose-dependent growth in normal and dwarfism mice
Safety
Vosoritide Injection site reactions, vomiting, blood pressure drops, excessive sweating. No hyperphosphatemia or eye issues
Infigratinib (low dose) Very clean. 4% mild transient hyperphosphatemia. No eye, skin, or blood pressure issues.
TYRA-300 (expected) Cleanest theoretically. No FGFR1/2/4 side effects expected. Unknown long-term.
Status
Vosoritide FDA approved since 2021, available now
Infigratinib Phase 3 completed, FDA submission planned H2 2026
TYRA-300 Phase 2 recruiting (BEACH301)
॰═════════════════॰
SIDE EFFECTS AND MANAGEMENT
॰═════════════════॰
Vosoritide
Injection site reactions very common
Management:
rotate sites (abdomen, thigh, arm), apply ice pack, use numbing cream 30 minutes before injection
Vomiting (20%)
Management:
give with small meal, anti-nausea meds if persistent
Blood pressure drop -
usually mild and brief
Management:
inject at bedtime so child sleeps through it, make sure well hydrated
Excessive sweating
Management:
usually mild, dress in layers
Limb pain
Management:
acetaminophen or ibuprofen, rest
Infigratinib (Low Dose for Growth)
Hyperphosphatemia (4%, mild)
Management:
usually self limiting, no intervention needed at this dose. Monitor phosphate levels.
Fatigue
Management:
rest, maintain activity as tolerated
Nausea
Management:
take with food, antinausea meds if needed
At the low dose used for achondroplasia, the severe side effects seen in cancer patients (eye problems, hand foot syndrome, nail damage) are not expected.
TYRA-300 (Expected)
Expected to be very clean due to FGFR3 selectivity
Unknown long-term effects
needs clinical data
Potential concerns
FGFR3 plays roles in hearing, skin, and bone quality. Deep inhibition may have effects not seen with less selective drugs.
General Monitoring for All Growth Therapies
Growth velocity measure height every 3-6 months
Bone age X-ray assess growth plate status and skeletal maturity
Body proportions
upper/lower segment ratio
Foramen magnum imaging
MRI in young children with achondroplasia
Spine imaging
monitor for spinal stenosis
Blood work
phosphate, calcium, liver function, kidney function
Eye exams
especially with less selective FGFR inhibitors
॰═════════════════॰
FUTURE DIRECTIONS
॰═════════════════॰
Earlier Treatment
Starting treatment as early as possible maximizes the total height gain because there are more years of growth remaining.
The PROPEL Infant and Toddler study is testing infigratinib from birth to age 3. Earlier intervention may also prevent complications like foramen magnum stenosis rather than just treating them.
Combination
Could vosoritide and infigratinib or TYRA 300 be combined?
Theoretically yes i think, one works downstream, the other at the source
But this has not been tested and would need careful safety evaluation so dont trust me
Other Short Stature Conditions
FGFR3 inhibition might help in conditions beyond achondroplasia:
Hypochondroplasia already shown effective with TYRA300
Idiopathic short stature
unknown, but wildtype mouse data suggest possible benefit
Growth hormone deficiency
unlikely to help, different mechanism, but paired well with hgh
Constitutional delay of growth unknown
The pediatric oncology cases where children on pan FGFR inhibitors grew faster than normal suggest FGFR3 inhibition could promote growth even without a genetic FGFR3 problem.
However, the risk of slipped capital femoral epiphysis (a serious hip condition where the growth plate slips)
Keeping Growth Plates Open
For people looking to maximize height, the key is keeping growth plates open as long as possible while maximizing growth velocity. Current strategies include:
Delaying puberty
aromatase inhibitors or GnRH agonists can delay estrogen-driven plate closure
Growth hormone increases IGF1, supports growth plate activity
FGFR3 inhibition
releases the brake on cartilage cell division
Good nutrition and sleep
foundational for any growth strategy
Combining these approaches theoretically could maximize height, but this is experimental and not standard of care.
॰═════════════════॰
REFERENCE LIST
॰═════════════════॰
FDA Voxzogo Vosoritide Label
PMC12352272 - Vosoritide Review
Rare Disease Advisor - Achondroplasia Management
PubMed 38590263 - Low-Dose Infigratinib Mouse Model
BridgeBio PROPEL 3 Results
EMPR - Infigratinib Growth Data
Rare Disease Advisor - PROPEL 3
PMC12128972 - TYRA-300 Preclinical Data
JCI Insight - TYRA-300 Study
Rare Disease Advisor - TYRA-300 Results
PMC5354942 - Achondroplasia Pathogenesis and Therapy
PMC3516592 - CNP Analog in Achondroplasia Mouse Model
Nature Communications - FGFR3 and Growth Plate CREB Signaling
NCT06995677 - BEACH301 TYRA-300 Phase 2
॰═════════════════॰
Vosoritide, Infigratinib, and TYRA300
How Bones Grow and Why Growth Plates Close
FGFR3 and Dwarfism
Vosoritide Voxzogo
Infigratinib PROPEL 3
TYRA-300
Overview
Side Effects and Management
Future development
Reference List
FGFR3 and Dwarfism
Vosoritide Voxzogo
Infigratinib PROPEL 3
TYRA-300
Overview
Side Effects and Management
Future development
Reference List
॰═════════════════॰
HOW BONES GROW AND WHY GROWTH PLATES CLOSE
॰═════════════════॰
The Growth Plate
Long bones grow from the ends at a structure called the growth plate or epiphyseal plate. This is a layer of cartilage between the end of the bone (the epiphysis) and the shaft (the diaphysis). The growth plate is where new bone is made, and it stays open during childhood and adolescence. Once it closes, usually in the late teens, height increase stops permanently.
The growth plate has several zones:
Resting zone
stem like cells that can become new cartilage cells
Proliferative zone
cells divide rapidly, stacking into columns like coins
Hypertrophic zone
cells swell up and prepare to turn into bone
Calcification zone
cartilage turns into hard bone
For height to increase, the proliferative and hypertrophic zones need to stay active. Anything that slows these zones down reduces growth velocity.
Endochondral Ossification
Endochondral ossification is the process where cartilage is replaced by bone. This is how all long bones grow in length. It requires a balance between cartilage cell production, swelling, and replacement by bone. If this balance is disrupted, bones grow shorter or stop growing early.
What Closes Growth Plates
Growth plates close when estrogen levels rise during puberty. Estrogen speeds up the rate at which cartilage cells in the growth plate turn into bone, eventually using up all the cartilage and fusing the epiphysis to the diaphysis. Once fused, the plate is closed and no more length can be added.
Some factors that keep growth plates open longer:
Lower estrogen levels delayed puberty or aromatase inhibitors
Growth hormone stimulates IGF1 which supports growth plate activity
Thyroid hormone necessary for normal growth plate function
Proper nutrition calories, protein, carbs, fats, vitamins, and minerals
Factors that close them early:
High estrogen
puberty, exogenous estrogen exposure
FGFR3 overactivity the focus of this thread
Chronic illness
malnutrition, inflammation, corticosteroid use
Trauma or infection
direct damage to the growth plate
॰═════════════════॰
FGFR3 AND DWARFISM
॰═════════════════॰
What FGFR3 Does Normally
FGFR3 is a receptor on cartilage cells in the growth plate. Its job is to act as a brake on bone growth. When FGFR3 gets a signal, it slows down cartilage cell division and speeds up their maturation into bone. This is a normal safety mechanism to prevent bones from growing too long.
Under normal conditions, FGFR3 signaling is balanced. It keeps growth in check but does not stop it completely.
When FGFR3 Is Broken
In achondroplasia, the most common form of dwarfism, a mutation in the FGFR3 gene makes the receptor stuck in the "on" position. Over 99% of achondroplasia cases are caused by the G380R mutation. This means the brake is slammed on all the time.
The result:
Proliferative zone shrinks
fewer cells dividing
Hypertrophic zone shrinks
less swelling and preparation for bone
Resting zone expands abnormally
stem cells get stuck and do not differentiate
Bones grow much slower
especially the long bones of the arms and legs
Disproportionate short stature
limbs are short relative to trunk
Other FGFR3related conditions:
Hypochondroplasia milder form, caused by N540K or other mutations
Severe achondroplasia with developmental delay and acanthosis
nigricans (SADDAN)
severe form
Thanatophoric dysplasia
lethal form, incompatible with life
Why Inhibiting FGFR3 Helps
If the problem is FGFR3 being stuck on, the solution is to turn it down. By blocking or inhibiting FGFR3 signaling, the brake is released. Cartilage cells can divide more, swell more, and the growth plate stays active longer. This leads to:
Increased growth velocity
faster height gain
Longer bones
especially femur and tibia
Better body proportions
reduced difference between upper and lower body segments
Larger foramen magnum
the opening at the base of the skull, reducing risk of life-threatening compression
Improved spinal shape
longer vertebrae and better disc shape, reducing spinal stenosis risk
This is the rationale behind all FGFR3 targeted therapies for growth.
Can This Work in Normal People
This is the big question. FGFR3 is not just broken in dwarfism it is active in everyone. Even in people with normal height, FGFR3 puts a brake on growth. If you inhibit FGFR3 in someone with normal FGFR3, you might:
Increase growth velocity
shown in wild-type mice treated with TYRA-300
Keep growth plates open longer
potentially delaying closure
Add extra height
if used before plates close
However, this is untested in humans without FGFR3 mutations. The data come from mouse studies and anecdotal reports from pediatric cancer patients receiving pan FGFR inhibitors who experienced accelerated growth. There are also risks:
Slipped capital femoral epiphysis
the growth plate can slip under too much growth pressure, requiring surgery
Unknown long-term bone quality
faster growth might mean weaker bones
Other FGFR3 functions
FGFR3 also plays roles in hearing, skin, and wound healing
The pediatric oncology cases are informative. Several children without short stature conditions received pan FGFR inhibitors for cancer and experienced annualized growth velocities above the normal range. Some developed slipped capital femoral epiphysis, a serious hip condition, attributed to the accelerated growth. This suggests FGFR inhibition can promote growth even without a genetic FGFR3 problem, but the risk benefit ratio needs careful evaluation.
॰═════════════════॰
VOSORITIDE VOXZOGO
BioMarin
॰═════════════════॰
Overview
Vosoritide is a recombinant Ctype natriuretic peptide (CNP) analog. CNP is a natural hormone in the body that counteracts FGFR3 signaling. Vosoritide is basically a lab made version of CNP that lasts longer in the body. It was approved by the FDA in November 2021 for children 5 years and older with achondroplasia who have open growth plates. In October 2023, approval was expanded to children under 5.
It is given as a daily subcutaneous injection (shot under the skin), which is a significant burden for families.
How It Works
Vosoritide binds to natriuretic peptide receptor B (NPR-B) on cartilage cells. This triggers production of cyclic guanosine monophosphate (cGMP), a signaling molecule inside the cell. cGMP then blocks the MAPK/ERK pathway, which is the main growth suppressing signal coming from FGFR3.
basically FGFR3 is the brake pedal. CNP/vosoritide is the hand that pulls the brake pedal back up, releasing it. The brake is still there, but it is not being pressed as hard.
Importantly, vosoritide does not directly block FGFR3. It works downstream, counteracting the signal. This means it is less potent than direct FGFR3 inhibitors but also has a different safety profile.
Clinical Results Phase 3
The pivotal trial enrolled 121 children with achondroplasia.
Annualized growth velocity increased by 1.57 cm/year compared to placebo (95% CI 1.22-1.93, p<0.0001)
AGV rose from 4.26 cm/year to 5.57 cm/year on treatment
Sustained efficacy over 156 weeks (3 years)
At 182 weeks, AGV remained stable at 5.45 cm/year
Improved body proportions
upper to lower body segment ratio improved by -0.05
85% of experts predicted meaningful proportionality gains for children starting between age 2 and puberty
Dosing
15 mcg/kg once daily by subcutaneous injection
Given at approximately the same time each day
Injected into fatty tissue under the skin (abdomen, thigh, or back of arm)
Side Effects and Management
Injection site reactions
redness, swelling, pain at injection site
Management: rotate injection sites, apply ice, use topical anesthetic cream before injection
Vomiting (20%)
take with food, antinausea medication if needed
Blood pressure drop
transient hypotension after injection
inject at bedtime to sleep through the effect, ensure adequate hydration
Hyperhidrosis (excessive sweating)
usually mild and self limiting
Limb pain
OTC pain relievers, rest
No hyperphosphatemia
because vosoritide does not block FGFR1 in the kidneys
No eye toxicity because it does not block FGFR2
No skin toxicity
because it does not block FGFR4
The main downside is the daily injection burden and the need for refrigeration. Compliance can be challenging for families.
making it a mogger compouns.
Limitations
Only works while growth plates are open
Requires daily injections
Moderate effect size (1.57 cm/year extra growth)
Does not address the root cause (FGFR3 is still overactive)
Very expensive
॰═════════════════॰
Links
FDA Voxzogo Vosoritide Label
PMC12352272 - Vosoritide Review Clinical and Real-World Evidence
Rare Disease Advisor - Achondroplasia Management Vosoritide
॰═════════════════॰
INFIGRATINIB PROPEL 3
BridgeBio
/
QED Therapeutics
॰═════════════════॰
Overview
Infigratinib is an oral FGFR13 inhibitor that was originally developed for cancer but is now being repositioned for achondroplasia at much lower doses. The PROPEL 3 Phase 3 trial was completed in early 2026 with positive results. This is the first oral drug to show statistically significant improvements in both growth velocity and body proportionality in achondroplasia.
BridgeBio plans to submit for FDA approval in the second half of 2026. It has already received Breakthrough Therapy and Orphan Drug designation from the FDA.
How It Works
Unlike vosoritide, which works downstream of FGFR3, infigratinib directly blocks FGFR3 at the source. It is an oral pill that inhibits the FGFR3 enzyme, preventing it from sending growth suppressing signals. At the low doses used for achondroplasia, it is selective enough to hit FGFR3 without causing the severe side effects seen at cancer doses.
Preclinical Data
In mouse models of achondroplasia:
Daily treatment at 2 mg/kg significantly increased bone growth
Low doses of 0.2 and 0.5 mg/kg also worked
Intermittent dosing (1 mg/kg every 3 days) was effective
Improved skull shape and enlarged foramen magnum
No changes in FGF23 or phosphorus levels at low doses
Positive impact on cartilage cell differentiation in the growth plate
PROPEL 3 Phase 3 Results
A global one year randomized double blind placebo controlled trial in children aged 3 to under 18 with achondroplasia and open growth plates.
Primary endpoint met
Change in annualized height velocity superior to placebo
Mean treatment difference +2.10 cm/year
LS mean treatment difference +1.74 cm/year (p<0.0001)
Secondary endpoints
Absolute AHV at Week 52: 5.96 cm/year vs 4.22 cm/year on placebo
Height Z-score improvement: +0.32 SD vs placebo (p<0.0001)
Largest improvement on treatment arm: +0.41 SD
Body proportionality
first drug to show statistically significant improvement
In children under 8 (over 50% of participants)
LS mean decrease in upper-to-lower ratio -0.05 vs placebo (p<0.05)
Overall population: LS mean decrease -0.05, treatment difference -0.02 vs placebo
Safety in PROPEL 3
No discontinuations due to side effects
No serious side effects related to the drug
Only 3 cases (4%) of hyperphosphatemia, all mild, temporary, without symptoms, and not requiring dose changes or stopping
No eye problems associated with FGFR1 or FGFR2 inhibition
No side effects seen with CNP analogs like blood pressure drops, injection site reactions, or excessive hair growth
This safety profile is dramatically better than the cancer dose because the achondroplasia dose is much lower.
Dosing for Growth
0.25 mg/kg/day oral once daily
This is roughly 1/500th of the cancer dose (125 mg/day), yet some people fearmonger and take 1mg
Much lower exposure means much less toxicity
Advantages Over Vosoritide
Oral pill
no injections
Once daily
easier than daily shots
Direct mechanism
blocks FGFR3 at the source rather than counteracting it downstream
Better body proportionality
first drug to show significant improvement
Potentially stronger effect
5.96 cm/year absolute AHV is among the highest reported
Ongoing Trials
PROPEL Infant and Toddler
study in children from birth to under 3 years
॰═════════════════॰
Links
BridgeBio PROPEL 3 Results
PubMed 38590263 - Low-Dose Infigratinib in Achondroplasia Mouse Model
EMPR - Infigratinib Improves Growth in Children
Rare Disease Advisor - PROPEL 3 Results
॰═════════════════॰
TYRA-300
Tyra Biosciences
॰═════════════════॰
Overview
TYRA300 is an also oral selective FGFR3 inhibitor being developed for both cancer and achondroplasia. It is the first drug designed to hit only FGFR3 while sparing FGFR1, FGFR2, and FGFR4. This selectivity is expected to eliminate the side effects that come from blocking the other FGFRs.
How It Works
TYRA 300 was designed using computer modeling to fit the exact shape of the FGFR3 enzyme. It binds to FGFR3 with over 100x selectivity compared to the other FGFRs. This means:
No FGFR1 blockade
no hyperphosphatemia
No FGFR2 blockade
no eye problems
No FGFR4 blockade
no liver or skin issues
Direct FGFR3 inhibition
stronger effect on the root cause
Preclinical Results in Mice
TYRA300 was tested in three types of mice:
Normal wild-type mice:
14 mg/kg increased nose-to-tail length by 7.3%
Tibia length increased 6.4%
Femur length increased 8.2%
Dose-dependent growth
more drug meant more growth
This proves FGFR3 inhibition can increase growth even in normal animals
Achondroplasia model mice (Fgfr3 Y367C/+)
Increased nose to tail, tail, tibia, and femur length
Partially restored normal body proportions
Growth plate zones expanded
more proliferative and hypertrophic activity
Improved skull shape and enlarged foramen magnum
Better bone mineral density and bone volume
Hypochondroplasia model mice (Fgfr3 N534K/+)
Femur increased 3.70%
Tibia increased 3.75%
Ulna increased 5.03%
Humerus increased 3.22%
Mechanism in Growth Plate
TYRA300 increased both proliferation (cell division) and differentiation (maturation) of cartilage cells in the growth plate. It restored type X collagen staining, which is a marker of healthy hypertrophic zone function. It also improved spinal shape longer lumbar vertebrae and better disc shape.
The foramen magnum (the hole at the base of the skull where the spinal cord passes through) was significantly enlarged. This is critical because foramen magnum stenosis is a life threatening complication in babies with achondroplasia.
Clinical Trials for Growth
BEACH301 Phase 2 NCT06995677
Status: Actively recruiting (sumbit your sons, if you have a kid)
Population: Children 3 to 10 years with achondroplasia and open growth plates
Design: Open label, multicenter
Goal: Evaluate safety and growth effects
Advantages
Oral pill
no injections
Selective for FGFR3 only
expected to have the cleanest safety profile
Works in both achondroplasia and hypochondroplasia
May work in other short stature conditions
preclinical data in normal mice suggest broader applicability
Improves both growth and bone quality
Safety Profile
Based on preclinical selectivity
No hyperphosphatemia
FGFR1 spared
No eye toxicity
FGFR2 spared
No liver or skin issues
FGFR4 spared
Unknown long-term effects
clinical data pending
Potential bone concerns
FGFR3 also plays roles in hearing, skin, and wound healing
॰═════════════════॰
Links
PMC12128972 - TYRA-300 Preclinical Bone Growth Data
JCI Insight - TYRA-300 Bone Growth Study
Rare Disease Advisor - TYRA-300 Preclinical Results
NCT06995677 - BEACH301 Phase 2
॰═════════════════॰
COMPARATIVE OVERVIEW
॰═════════════════॰
Mechanism Comparison
Vosoritide
Indirect. Mimics CNP, works downstream of FGFR3 by boosting cGMP and blocking MAPK/ERK. Does not touch FGFR3 directly.
Infigratinib
Direct. Blocks FGFR1-3 enzymes. At low doses, mainly hits FGFR3.
TYRA-300
Direct and selective. Blocks only FGFR3, spares FGFR1/2/4.
Route of Administration
Vosoritide Daily subcutaneous injection
Infigratinib Oral once daily
TYRA-300 Oral once daily
Efficacy Comparison
Vosoritide +1.57 cm/year extra growth, AGV 5.57 cm/year
Infigratinib +1.74 to +2.10 cm/year extra growth, AGV 5.96 cm/year, first to improve body proportionality significantly
TYRA-300 Preclinical only, but showed dose-dependent growth in normal and dwarfism mice
Safety
Vosoritide Injection site reactions, vomiting, blood pressure drops, excessive sweating. No hyperphosphatemia or eye issues
Infigratinib (low dose) Very clean. 4% mild transient hyperphosphatemia. No eye, skin, or blood pressure issues.
TYRA-300 (expected) Cleanest theoretically. No FGFR1/2/4 side effects expected. Unknown long-term.
Status
Vosoritide FDA approved since 2021, available now
Infigratinib Phase 3 completed, FDA submission planned H2 2026
TYRA-300 Phase 2 recruiting (BEACH301)
॰═════════════════॰
SIDE EFFECTS AND MANAGEMENT
॰═════════════════॰
Vosoritide
Injection site reactions very common
Management:
rotate sites (abdomen, thigh, arm), apply ice pack, use numbing cream 30 minutes before injection
Vomiting (20%)
Management:
give with small meal, anti-nausea meds if persistent
Blood pressure drop -
usually mild and brief
Management:
inject at bedtime so child sleeps through it, make sure well hydrated
Excessive sweating
Management:
usually mild, dress in layers
Limb pain
Management:
acetaminophen or ibuprofen, rest
Infigratinib (Low Dose for Growth)
Hyperphosphatemia (4%, mild)
Management:
usually self limiting, no intervention needed at this dose. Monitor phosphate levels.
Fatigue
Management:
rest, maintain activity as tolerated
Nausea
Management:
take with food, antinausea meds if needed
At the low dose used for achondroplasia, the severe side effects seen in cancer patients (eye problems, hand foot syndrome, nail damage) are not expected.
TYRA-300 (Expected)
Expected to be very clean due to FGFR3 selectivity
Unknown long-term effects
needs clinical data
Potential concerns
FGFR3 plays roles in hearing, skin, and bone quality. Deep inhibition may have effects not seen with less selective drugs.
General Monitoring for All Growth Therapies
Growth velocity measure height every 3-6 months
Bone age X-ray assess growth plate status and skeletal maturity
Body proportions
upper/lower segment ratio
Foramen magnum imaging
MRI in young children with achondroplasia
Spine imaging
monitor for spinal stenosis
Blood work
phosphate, calcium, liver function, kidney function
Eye exams
especially with less selective FGFR inhibitors
॰═════════════════॰
FUTURE DIRECTIONS
॰═════════════════॰
Earlier Treatment
Starting treatment as early as possible maximizes the total height gain because there are more years of growth remaining.
The PROPEL Infant and Toddler study is testing infigratinib from birth to age 3. Earlier intervention may also prevent complications like foramen magnum stenosis rather than just treating them.
Combination
Could vosoritide and infigratinib or TYRA 300 be combined?
Theoretically yes i think, one works downstream, the other at the source
But this has not been tested and would need careful safety evaluation so dont trust me
Other Short Stature Conditions
FGFR3 inhibition might help in conditions beyond achondroplasia:
Hypochondroplasia already shown effective with TYRA300
Idiopathic short stature
unknown, but wildtype mouse data suggest possible benefit
Growth hormone deficiency
unlikely to help, different mechanism, but paired well with hgh
Constitutional delay of growth unknown
The pediatric oncology cases where children on pan FGFR inhibitors grew faster than normal suggest FGFR3 inhibition could promote growth even without a genetic FGFR3 problem.
However, the risk of slipped capital femoral epiphysis (a serious hip condition where the growth plate slips)
Keeping Growth Plates Open
For people looking to maximize height, the key is keeping growth plates open as long as possible while maximizing growth velocity. Current strategies include:
Delaying puberty
aromatase inhibitors or GnRH agonists can delay estrogen-driven plate closure
Growth hormone increases IGF1, supports growth plate activity
FGFR3 inhibition
releases the brake on cartilage cell division
Good nutrition and sleep
foundational for any growth strategy
Combining these approaches theoretically could maximize height, but this is experimental and not standard of care.
॰═════════════════॰
REFERENCE LIST
॰═════════════════॰
FDA Voxzogo Vosoritide Label
PMC12352272 - Vosoritide Review
Rare Disease Advisor - Achondroplasia Management
PubMed 38590263 - Low-Dose Infigratinib Mouse Model
BridgeBio PROPEL 3 Results
EMPR - Infigratinib Growth Data
Rare Disease Advisor - PROPEL 3
PMC12128972 - TYRA-300 Preclinical Data
JCI Insight - TYRA-300 Study
Rare Disease Advisor - TYRA-300 Results
PMC5354942 - Achondroplasia Pathogenesis and Therapy
PMC3516592 - CNP Analog in Achondroplasia Mouse Model
Nature Communications - FGFR3 and Growth Plate CREB Signaling
NCT06995677 - BEACH301 TYRA-300 Phase 2
॰═════════════════॰
